NCT00788684 - Safety Study of ABT-263 in Combination With Rituximab in Lymphoid Cancers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

July 21, 2009

Primary Completion Date

February 7, 2025

Study Completion Date

February 7, 2025

Conditions

CD20-Positive Lymphoid MalignanciesChronic Lymphoid LeukemiaHematological MalignanciesNon-Hodgkin's Lymphoma

Interventions

DRUG

rituximab

IV infusion once weekly for four doses

DRUG

ABT-263

ABT-263: oral solution or tablets, once daily dosing until disease progression

Trial Locations (6)

Peter MacCallum Cancer Ctr /ID# 25067, Melbourne

The Royal Melbourne Hospital /ID# 9781, Parkville

Cleveland Clinic Main Campus /ID# 9784, Cleveland

University of Arizona Cancer Center - North Campus /ID# 16721, Tucson

Stanford University School of Med /ID# 9782, Stanford

Univ of Wisconsin Hosp/Clinics /ID# 21701, Madison